Ocugen, Inc. Common Stock (OCGN)

Price$1.37

Value ScoreF

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)8.39%

Price vs S&P 500 (4W)-28.31%

VGM Score36.72

Market Capitalization$467.16M

All Metrics

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)1.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)366.28%

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)-8.71%

Net Profit Margin (TTM)-1158.59%

EPS (TTM)$-0.17

10-Day Avg Trading Volume5.73M

EPS Excl Extra (TTM)$-0.17

EPS (Annual)$-0.23

ROI (Annual)-92.71%

Net Profit Margin (5Y Avg)-119113.09%

Cash / Share (Quarterly)$0.09

Revenue Growth QoQ (YoY)3.51%

ROA (Last FY)-155.91%

Revenue Growth TTM (YoY)3.01%

EBITD / Share (TTM)$-0.15

ROE (5Y Avg)-119.32%

Operating Margin (TTM)-1057.51%

Cash Flow / Share (Annual)$-0.18

P/B Ratio80.48x

P/B Ratio (Quarterly)102.24x

Net Income / Employee (Annual)$-584,900

EV / Revenue (TTM)99.72x

Net Interest Coverage (TTM)-14.90x

ROA (TTM)-96.32%

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)1.06x

Quick Ratio (Quarterly)1.54x

3-Month Avg Trading Volume7.66M

52-Week Price Return65.47%

Revenue / Employee (TTM)$40,200

Tangible BV / Share (Quarterly)$45.33

P/S Ratio (Annual)105.86x

Asset Turnover (Annual)0.10x

52-Week High$2.73

Operating Margin (5Y Avg)-45112.35%

EPS Excl Extra (Annual)$-0.23

CapEx CAGR (5Y)-9.81%

26-Week Price Return24.32%

Quick Ratio (Annual)0.81x

13-Week Price Return-26.20%

Total Debt / Equity (Annual)0.97x

Current Ratio (Quarterly)1.86x

Enterprise Value$464.50M

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-13.42%

Revenue / Employee (Annual)$38,000

Pretax Margin (Annual)-1537.41%

Cash / Share (Annual)$0.06

3-Month Return Std Dev97.67%

Net Income / Employee (TTM)$-465,200

ROE (Last FY)-182.42%

Net Interest Coverage (Annual)-15.10x

EPS Basic Excl Extra (Annual)$-0.23

Total Debt / Equity (Quarterly)5.03x

EPS Incl Extra (TTM)$-0.17

ROI (TTM)-165.19%

P/S Ratio (TTM)100.29x

Pretax Margin (5Y Avg)-63113.09%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$45.33

Price vs S&P 500 (52W)37.26%

Year-to-Date Return2.22%

5-Day Price Return2.99%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-89.86%

Net Profit Margin (Annual)-1537.41%

Month-to-Date Return-20.23%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-1425.70%

LT Debt / Equity (Annual)0.92x

ROI (5Y Avg)-96.85%

LT Debt / Equity (Quarterly)4.17x

EPS Basic Excl Extra (TTM)$-0.17

P/TBV (Quarterly)1.94x

P/B Ratio (Annual)7.91x

Pretax Margin (TTM)-1158.59%

Book Value / Share (Annual)$0.10

Price vs S&P 500 (13W)-35.95%

Beta2.18x

Revenue / Share (TTM)$0.01

ROE (TTM)-1306.71%

52-Week Low$0.80

vGradeF

gGradeC

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.06est. -0.05

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.09

4.15

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
OCGNOcugen, Inc. Common Stock	F	C	C	$1.37
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Ocugen Inc develops gene therapies, cell therapies, and vaccines targeting unmet medical needs across multiple therapeutic areas. The company's primary focus is on retinal diseases, including inherited conditions such as retinitis pigmentosa and Leber congenital amaurosis, as well as age-related diseases including dry age-related macular degeneration and geographic atrophy. Its pipeline includes modifier gene therapy, novel biologics, regenerative medicine cell therapies, and inhaled mucosal vaccine platforms.